Objective:
To evaluate the efficacy and safety of monthly dosing of aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) who have been previously treated with anti-VEGF agents.
Approach:
- Visual acuity benefits were observed in both nAMD and DME patients.
- Central retinal thickness improvements were noted.
- Safety data was consistent with previous pivotal trials.
- The study specifically focused on patients previously treated with anti-VEGF agents, which may limit generalizability.
Key Findings:
Interpretation:
The updated label allows for the use of aflibercept 8 mg in hard-to-treat patients.
Limitations:
Conclusion:
The findings support the use of monthly aflibercept 8 mg in refractory cases of nAMD and DME.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
